Lataa...
Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
Sulbactam-durlobactam is being developed for the treatment of infections caused by Acinetobacter baumannii, including those caused by multidrug- and carbapenem-resistant isolates. This was a phase 1 study to evaluate the effects of various degrees of renal impairment, including subjects with end-sta...
Tallennettuna:
| Julkaisussa: | Antimicrob Agents Chemother |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Microbiology
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6709459/ https://ncbi.nlm.nih.gov/pubmed/31307978 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00794-19 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|